Published in Blood on May 01, 1998
Genomic imprinting: implications for human disease. Am J Pathol (1999) 2.26
Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A (2000) 0.99
Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet (2013) 0.95
Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS One (2012) 0.92
Upregulation of IGF2 expression during vascular calcification. J Mol Endocrinol (2014) 0.86
Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5. PLoS One (2014) 0.80
Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett (2011) 0.80
Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. Clin Epigenetics (2015) 0.78
The epigenome as a potential mediator of cancer and disease prevention in prenatal development. Nutr Rev (2013) 0.78
Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. J Gastroenterol (2016) 0.78
Replication status as a possible marker for genomic instability in cells originating from genotypes with balanced rearrangements. Chromosome Res (2001) 0.77
Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis. Leukemia (2015) 0.76
Paternal Insulin-like Growth Factor 2 (Igf2) Regulates Stem Cell Activity During Adulthood. EBioMedicine (2016) 0.75
IGF2-derived miR-483 mediated oncofunction by suppressing DLC-1 and associated with colorectal cancer. Oncotarget (2016) 0.75
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Epigenetic memory in induced pluripotent stem cells. Nature (2010) 14.31
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 7.52
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Relaxation of imprinted genes in human cancer. Nature (1993) 3.86
Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (1985) 3.72
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol (2001) 3.24
Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci U S A (1999) 3.22
Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet (1997) 3.01
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med (1998) 2.91
Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet (1994) 2.90
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet (1996) 2.78
Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature (1984) 2.77
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science (1985) 2.49
Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature (1995) 2.43
Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun (1983) 2.41
A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol Cell Biol (1993) 2.32
Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia (1997) 2.26
Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A (1996) 2.17
Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest (2000) 2.17
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
LIT1, an imprinted antisense RNA in the human KvLQT1 locus identified by screening for differentially expressed transcripts using monochromosomal hybrids. Hum Mol Genet (1999) 2.16
Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci U S A (1994) 2.09
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Spatiotemporal regulation of cell-cycle genes by SHORTROOT links patterning and growth. Nature (2010) 2.05
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04
Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma (1994) 2.04
Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst (2001) 2.02
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood (1992) 2.00
Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet (1989) 1.99
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature (1985) 1.91
Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med (1995) 1.91
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Hot-stop PCR: a simple and general assay for linear quantitation of allele ratios. Nat Genet (2000) 1.88
Multiple genetic alterations in distal and proximal colorectal cancer. Lancet (1989) 1.87
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Sequence and comparative analysis of the mouse 1-megabase region orthologous to the human 11p15 imprinted domain. Genome Res (2000) 1.85
Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science (1983) 1.83
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Concerted nonsyntenic allelic loss in human colorectal carcinoma. Science (1988) 1.81
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia (2008) 1.79
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia. Leukemia (1997) 1.73
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Treatment of myelogenous leukemia: current status and investigational options. Blood (1996) 1.70
Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res (2001) 1.69
Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther (2003) 1.69
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene (2009) 1.64
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.63
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol (1997) 1.60
Evaluation of an emergency department-based injury surveillance project in China using WHO guidelines. Inj Prev (2009) 1.60
Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet (1997) 1.58
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) (1988) 1.56
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55
Physiology and pathophysiology of dendritic cells. Hum Pathol (1997) 1.54
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia (2010) 1.51
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res (2001) 1.51
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Syntenic organization of the mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann syndrome region in chromosome 11p15.5. Hum Mol Genet (1998) 1.49